Pro-Pharmaceuticals, Inc. (Amex: PRW), a developer of novel carbohydrate compounds, today announced it has requested a meeting with the U.S. Food & Drug Administration (FDA) to discuss data and plans for submitting a New Drug Application (NDA), under Section 505 (b)(2), for DAVANAT® to be co-administered with 5-Fluorouracil (5-FU) to treat cancer patients.
